Larimar Therapeutics
LRMR
37 hedge funds and large institutions have $166M invested in Larimar Therapeutics in 2020 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 16 closing their positions.
1,300% more call options, than puts
Call options by funds: $42K | Put options by funds: $3K
721% more capital invested
Capital invested by funds: $20.2M → $166M (+$146M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
78.49% more ownership
Funds ownership: 5.85% → 84.33% (+78%)
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
12% less funds holding
Funds holding: 42 → 37 (-5)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$59.9M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$17.6M |
| 3 |
CA
CHI Advisors
New York
|
+$17.6M |
| 4 |
O
OrbiMed
New York
|
+$9.8M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
+$9.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.23M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$946K |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$550K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
-$140K |
| 5 |
HP
Hikari Power
Tokyo,
Japan
|
-$116K |
LRMR Hedge Fund Activity: Q2 2020 in Review
37 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q2 2020, worth a combined $166M — up 721% from $20.2M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of LRMR and 11 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 11 added.
The largest buyer was Deerfield Management, opening a new position worth an estimated $59.9M. The largest seller was Morgan Stanley, cutting an estimated $1.23M.
- 37 institutional investors held Larimar Therapeutics (LRMR) as of Q2 2020, down from 42 in Q1 2020.
- Funds reported $166M of Larimar Therapeutics stock for Q2 2020, up 721% quarter-over-quarter.
- 11 funds opened new Larimar Therapeutics positions in Q2 2020 and 16 closed out, a net change of -5 holders.
- The largest Larimar Therapeutics buyer in Q2 2020 was Deerfield Management, an estimated $59.9M added.
- The largest Larimar Therapeutics seller in Q2 2020 was Morgan Stanley, an estimated $1.23M sold.
Based on aggregated 13F filings for Q2 2020.